Recombinant enteroviruses and uses thereof
AssigneesThe Regents of the University of California, Aleph Therapeutics, Inc.
InventorsRaul ANDINO-PAVLOVSKY, Yinghong XIAO, Gilad DOITSH, Robert NAKAMURA, Dale TALBOT
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to, inter alia, to nucleic acid constructs encoding a modified enterovirus genome that is devoid of partial or complete nucleic acid sequences encoding viral structural proteins. The disclosure also provides compositions and methods useful for producing defective interfering particles (DIPs) of enteroviruses, and for the prevention and/or treatment of various health conditions such as immune diseases and viral infections.
Claims52
A nucleic acid construct comprising a nucleic acid sequence encoding a modified enterovirus genome, wherein the modified enterovirus genome is devoid of at least a portion of the nucleic acid sequence encoding viral structural proteins.
Dependencies are inferred from the claim text.